{"id":"bivalent-bnt162b2-original-omi-ba-4-ba-5","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pain medications (e.g., ibuprofen, naproxen)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Blood thinners (e.g., heparin, enoxaparin)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants (e.g., apixaban, rivaroxaban)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelet agents (e.g., clopidogrel, prasugrel)","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Live vaccines","action":"Avoid","effect":"Reduced efficacy of vaccine"},{"drug":"Interferon-alpha","action":"Avoid","effect":"Reduced efficacy of vaccine"},{"drug":"Immunosuppressants (e.g., corticosteroids, cyclosporine)","action":"Avoid","effect":"Reduced efficacy of vaccine"}],"commonSideEffects":[{"effect":"Fatigue (FATIGUE)","drugRate":"54.2%","placeboRate":"","totalAtRisk":288,"totalAffected":156,"trialsReporting":3},{"effect":"Injection site pain (PAIN)","drugRate":"82.8%","placeboRate":"","totalAtRisk":134,"totalAffected":111,"trialsReporting":2},{"effect":"Headache (HEADACHE)","drugRate":"36.1%","placeboRate":"","totalAtRisk":288,"totalAffected":104,"trialsReporting":3},{"effect":"Injection site pain (PAIN AT THE INJECTION SITE)","drugRate":"57.1%","placeboRate":"","totalAtRisk":154,"totalAffected":88,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"18.8%","placeboRate":"","totalAtRisk":288,"totalAffected":54,"trialsReporting":3},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"38.1%","placeboRate":"","totalAtRisk":134,"totalAffected":51,"trialsReporting":2},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"12.5%","placeboRate":"","totalAtRisk":288,"totalAffected":36,"trialsReporting":3},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"17.9%","placeboRate":"","totalAtRisk":134,"totalAffected":24,"trialsReporting":2},{"effect":"Injection site swelling (SWELLING)","drugRate":"8.3%","placeboRate":"","totalAtRisk":288,"totalAffected":24,"trialsReporting":3},{"effect":"Injection site erythema (REDNESS)","drugRate":"7.6%","placeboRate":"","totalAtRisk":288,"totalAffected":22,"trialsReporting":3},{"effect":"Myalgia (NEW OR WORSENED MUSCLE PAIN)","drugRate":"13.0%","placeboRate":"","totalAtRisk":154,"totalAffected":20,"trialsReporting":1},{"effect":"Arthralgia (NEW OR WORSENED JOINT PAIN)","drugRate":"8.4%","placeboRate":"","totalAtRisk":154,"totalAffected":13,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"4.2%","placeboRate":"","totalAtRisk":288,"totalAffected":12,"trialsReporting":3},{"effect":"Vomiting (VOMITING)","drugRate":"2.1%","placeboRate":"","totalAtRisk":288,"totalAffected":6,"trialsReporting":3},{"effect":"COVID-19","drugRate":"0.9%","placeboRate":"","totalAtRisk":336,"totalAffected":3,"trialsReporting":4},{"effect":"Headache","drugRate":"2.0%","placeboRate":"","totalAtRisk":152,"totalAffected":3,"trialsReporting":2},{"effect":"Rash","drugRate":"1.9%","placeboRate":"","totalAtRisk":154,"totalAffected":3,"trialsReporting":1},{"effect":"Dermatitis contact","drugRate":"3.3%","placeboRate":"","totalAtRisk":30,"totalAffected":1,"trialsReporting":1},{"effect":"Back pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":134,"totalAffected":0,"trialsReporting":2},{"effect":"Bell's palsy","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Blood pressure increased","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"0.0%","placeboRate":"","totalAtRisk":258,"totalAffected":0,"trialsReporting":2},{"effect":"Ear pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Fatigue","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Hypercholesterolaemia","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":134,"totalAffected":0,"trialsReporting":2},{"effect":"Joint abscess","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Lymphadenopathy","drugRate":"0.0%","placeboRate":"","totalAtRisk":134,"totalAffected":0,"trialsReporting":2},{"effect":"Myalgia","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Otitis media","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Sinusitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Thermal burn","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":134,"totalAffected":0,"trialsReporting":2},{"effect":"Urinary tract infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":134,"totalAffected":0,"trialsReporting":2},{"effect":"Vomiting","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal mycotic infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Vulvovaginal pruritus","drugRate":"0.0%","placeboRate":"","totalAtRisk":104,"totalAffected":0,"trialsReporting":1},{"effect":"Palpitations","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Chest pain","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Injection site erythema","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Conjunctivitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Viral infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Animal bite","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Muscle strain","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"SARS-CoV-2 test positive","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Menstruation irregular","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Cough","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Productive cough","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1},{"effect":"Wheezing","drugRate":"0.0%","placeboRate":"","totalAtRisk":30,"totalAffected":0,"trialsReporting":1}],"contraindications":["Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.","Events of anaphylaxis have been reported.","Subsequent dose(s) of the vaccine should not be given to those who have experienced anaphylaxis to the earlier dose of COMIRNATY.","Myocarditis and pericarditis","Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection.","Thrombocytopenia and coagulation disorders","Immunocompromised individuals"],"specialPopulations":{"Pregnancy":"The participants in this study had all received COVID-19 vaccines during pregnancy. According to the previous literature, a COVID booster vaccine administered during pregnancy can provide protection against SARS-CoV-2 Omicron subvariants, including BA.5, BF.7, BQ.1, and XBB.1.5. The bivalent COVID-19 vaccine delivers strong Nab inhibition against multiple SARS-CoV-2 Omicron subvariants in maternal blood.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bivalent-bnt162b2-original-omi-ba-4-ba-5","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:24.781853+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:30.319639+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:24.849038+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bivalent-bnt162b2-original-omi-ba-4-ba-5","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:31.231252+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5791340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:32.590604+00:00"}},"allNames":"bivalent bnt162b2 (original/omi ba.4/ba.5)","offLabel":[],"timeline":[],"aiSummary":"Pfizer's bivalent BNT162b2 (original/Omi BA.4/BA.5) is a marketed COVID-19 vaccine. It is developed by Pfizer Inc. The vaccine works by targeting the SARS-CoV-2 virus. It is indicated for COVID-19 prevention in individuals 5 years of age and older, and in individuals 6 months through 4 years of age. The vaccine has undergone 4 clinical trials and has generated $63.6B in revenue. It is a key player in the COVID-19 vaccine market. Pfizer continues to develop its pipeline of COVID-19 vaccines.","brandName":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2 virus","novelty":"best-in-class","modality":"mRNA vaccine","drugClass":"mRNA vaccine","explanation":"","oneSentence":"","technicalDetail":"The bivalent BNT162b2 (original/Omi BA.4/BA.5) vaccine uses a lipid nanoparticle to deliver the mRNA to the cells, where it is translated into the SARS-CoV-2 protein. The immune system recognizes the protein as foreign and mounts an immune response, producing antibodies and immune cells that can recognize and fight the virus. The vaccine has been shown to be safe and effective in clinical trials, with a strong immune response and a favorable safety profile."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=bivalent-bnt162b2-original-omi-ba-4-ba-5","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bivalent-bnt162b2-original-omi-ba-4-ba-5","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:28:21.557113+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"BNT162b2-Omi.BA.1","company":"Unknown","advantage":"Uses the same lipid-nanoparticle formulation and nucleoside-modified mRNA platform as original BNT162b2 but includes coding sequences of the Omicron BA.1 spike protein"},{"name":"Original BNT162b2","company":"Unknown","advantage":"Uses the same lipid-nanoparticle formulation and nucleoside-modified mRNA platform as bivalent BNT162b2-Omi.BA.4/BA.5 but includes coding sequences of the original spike protein"}],"genericName":"bivalent-bnt162b2-original-omi-ba-4-ba-5","indications":{"approved":[{"name":"COVID-19 prevention in individuals 5 years of age and older","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 5 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 6 months through 4 years of age with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose","regulator":"FDA"},{"name":"COVID-19 prevention in individuals 12 years of age and older with a third dose administered at least 2 months after the second dose and a fourth dose administered at least 2 months after the third dose and a fifth dose administered at least 2 months after the fourth dose and a sixth dose administered at least 2 months after the fifth dose and a seventh dose administered at least 2 months after the sixth dose and an eighth dose administered at least 2 months after the seventh dose and a ninth dose administered at least 2 months after the eighth dose and a tenth dose administered at least 2 months after the ninth dose and an eleventh dose administered at least 2 months after the tenth dose and a twelfth dose administered at least 2 months after the eleventh dose","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT05472038","phase":"PHASE2, PHASE3","title":"A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-07-26","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":1453},{"nctId":"NCT05596734","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-10-28","conditions":"Influenza, Human, COVID-19","enrollment":1019},{"nctId":"NCT05886777","phase":"PHASE2","title":"A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-05","conditions":"Healthy Participants","enrollment":1142}],"_emaApprovals":[{"date":"","name":"bivalent BNT162b2 (original/Omi BA.4/BA.5)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5791340"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"mRNA vaccine","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":4,"withResults":4},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:28:21.557113+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}